Evidence map›Paper›PMID 41170728›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?

Anne Ravix, Ermindo Roberto Di Paolo, Kim Dao, Maria-Helena Perez, Pierre Alex Crisinel, Thierry Buclin, Pascal André, Catia Marzolini, Chantal Csajka, Monia Guidi

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anne RavixCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Ermindo Roberto Di PaoloPharmacy Service, Lausanne University Hospital, Lausanne, Switzerland.
Kim DaoService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6033-3435
Maria-Helena PerezDepartment of Women Mother Child, Pediatric Intensive and Intermediate Care Units, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pierre Alex CrisinelDepartment of Woman Mother and Child, Unit of Pediatric Infectious Diseases and Vaccinology, Service of Pediatrics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Thierry BuclinService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0639-5536
Pascal AndréService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Catia MarzoliniService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Chantal CsajkaCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-0660-082X
Monia GuidiCentre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6419-9317

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAppropriate dosing of piperacillin/tazobactam is crucial for hospitalized children and might be a challenge in case of augmented renal clearance. This study assessed the appropriateness of piperacillin dosing regimens recommended to attain pharmacokinetic/pharmacodynamic targets by pediatric guidelines using a population pharmacokinetic approach.

methodsA population pharmacokinetic model for piperacillin was developed using therapeutic drug monitoring observations collected in hospitalized children between 2012 and 2021. Subsequently, simulations were performed to evaluate whether dosing regimens recommended by various pediatric guidelines achieved the pharmacodynamic target [i.e. maintaining free piperacillin plasma concentrations above the minimum inhibitory concentration for 100% of the dosing interval (100% fT > MIC)] in case of augmented, normal and moderately impaired renal functions.

resultsThe model best describing our 386 concentration values in 104 patients was a two-compartment model with allometric scaling of pharmacokinetic parameters based on bodyweight. Renal function also influenced clearance. Simulations revealed a risk of underdosing in patients with a creatinine clearance above 50 mL/min/1.73 m2 when piperacillin was administered as intermittent infusions, according to most guidelines. In contrast, continuous infusions consistently achieved the pharmacodynamic target even for MIC close to the limit of susceptibility.

conclusionThis study highlights the critical impact of renal function on piperacillin pharmacokinetics in pediatric patients. Continuous infusion regimens are necessary to ensure optimal drug exposure and efficacy, particularly in patients with augmented creatinine clearance. These results emphasize the need to revise pediatric dosing strategies considering a broader range of renal function.

Indexed as

Anti-Bacterial AgentsKidneyPiperacillinPiperacillin, Tazobactam Drug CombinationAdolescentChildChild, PreschoolDrug MonitoringFemaleHumansInfantMaleMicrobial Sensitivity TestsPractice Guidelines as TopicAnti-Bacterial AgentsPiperacillinPiperacillin, Tazobactam Drug Combination

Identifiers

PMID41170728
PMCPMC12670153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.